Goldman resumed coverage of HCA with a rating of Buy and set a new price target of $470.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2026 | $427.00 | Overweight → Equal Weight | Barclays |
| 12/15/2025 | $425.00 | Equal-Weight → Underweight | Morgan Stanley |
| 10/14/2025 | $470.00 | Buy | Goldman |
| 7/28/2025 | Outperform → Peer Perform | Wolfe Research | |
| 7/16/2025 | $394.00 | Buy → Neutral | BofA Securities |
| 5/29/2025 | $385.00 | Underweight → Equal Weight | Wells Fargo |
| 4/15/2025 | $336.00 | Outperform → Neutral | Robert W. Baird |
| 12/17/2024 | $380.00 | Neutral | Analyst |
HCA Healthcare, Inc. (NYSE:HCA) announces the following Webcast: What: HCA Healthcare, Inc. 2Q 2026 Earnings Call When: Friday, July 24, 2026, at 9:00 AM Central (10:00 AM Eastern) How: Live Audio over the Internet: https://investor.hcahealthcare.com/events-and-presentations/default.aspx Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, frank.morgan@hcahealthcare.com If you are unable to listen during the live webcast, the call will be archived on the web site: https://investor.hcahealthcare.com/events-and-presentations/default.aspx. View source version on businesswire.com: https://www.businesswire.com/news/home/20260714544676/en/ INVESTOR CONTACT: Frank Morg
Revises 2026 Guidance HCA Healthcare, Inc. (NYSE:HCA) today announced preliminary financial and operating results for the second quarter ended June 30, 2026. The preliminary financial and operating results are subject to finalization of the Company's quarterly financial and accounting procedures. HCA anticipates revenues in the second quarter of 2026 to approximate $20.230 billion, compared to $18.605 billion in the second quarter of 2025. Net income attributable to HCA Healthcare, Inc. is expected to approximate $1.699 billion, or $7.62 per diluted share, compared to $1.653 billion, or $6.83 per diluted share, in the second quarter of 2025. Results for the second quarter of 2026 includ
First published data evaluating gene-editing treatment in children ages 5-11 with inherited blood disorders highlights the potential for earlier intervention before cumulative injury HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced new research published in The New England Journal of Medicine (NEJM) demonstrating promising results from a gene-editing therapy being investigated in children ages 5-11 with severe sickle cell disease and transfusion-dependent beta thalassemia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629348492/en/The current NEJM study builds on HCA Health
8-K - HCA Healthcare, Inc. (0000860730) (Filer)
8-K - HCA Healthcare, Inc. (0000860730) (Filer)
8-K - HCA Healthcare, Inc. (0000860730) (Filer)
Barclays downgraded HCA from Overweight to Equal Weight and set a new price target of $427.00
Morgan Stanley downgraded HCA from Equal-Weight to Underweight and set a new price target of $425.00
Goldman resumed coverage of HCA with a rating of Buy and set a new price target of $470.00
4 - HCA Healthcare, Inc. (0000860730) (Issuer)
4 - HCA Healthcare, Inc. (0000860730) (Issuer)
4 - HCA Healthcare, Inc. (0000860730) (Issuer)
4 - HCA Healthcare, Inc. (0000860730) (Issuer)
HCA Healthcare, Inc. (NYSE:HCA) announces the following Webcast: What: HCA Healthcare, Inc. 2Q 2026 Earnings Call When: Friday, July 24, 2026, at 9:00 AM Central (10:00 AM Eastern) How: Live Audio over the Internet: https://investor.hcahealthcare.com/events-and-presentations/default.aspx Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, frank.morgan@hcahealthcare.com If you are unable to listen during the live webcast, the call will be archived on the web site: https://investor.hcahealthcare.com/events-and-presentations/default.aspx. View source version on businesswire.com: https://www.businesswire.com/news/home/20260714544676/en/ INVESTOR CONTACT: Frank Morg
Revises 2026 Guidance HCA Healthcare, Inc. (NYSE:HCA) today announced preliminary financial and operating results for the second quarter ended June 30, 2026. The preliminary financial and operating results are subject to finalization of the Company's quarterly financial and accounting procedures. HCA anticipates revenues in the second quarter of 2026 to approximate $20.230 billion, compared to $18.605 billion in the second quarter of 2025. Net income attributable to HCA Healthcare, Inc. is expected to approximate $1.699 billion, or $7.62 per diluted share, compared to $1.653 billion, or $6.83 per diluted share, in the second quarter of 2025. Results for the second quarter of 2026 includ
HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the first quarter ended March 31, 2026. Key first quarter metrics (all percentage changes compare 1Q 2026 to 1Q 2025 unless otherwise noted): Revenues increased 4.3 percent to $19.109 billion Net income attributable to HCA Healthcare, Inc. increased 0.6 percent to $1.620 billion Diluted earnings per share and diluted earnings per share, as adjusted, increased 10.9 percent to $7.15 per diluted share Adjusted EBITDA increased 1.9 percent to $3.802 billion Cash flows from operating activities increased 22.0 percent to $2.014 billion Same facility admissions increased 0.9 percent and same fac
HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today presented its annual HCA Healthcare Awards of Distinction at a ceremony in Nashville, Tennessee. The HCA Healthcare Awards of Distinction—comprising the Frist Humanitarian Award and the Excellence in Nursing Award—are the highest honors HCA Healthcare bestows on employees, physicians and volunteers, recognizing the extraordinary individuals who exemplify the organization's culture and values. The Frist Humanitarian Award recognizes the highest achievements in serving others, and the HCA Healthcare Excellence in Nursing Award recognizes the highest levels of performance in the field of nursing. "The
HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that its board of directors has appointed John W. Chidsey, III as an independent director, effective July 15, 2025. With his addition, HCA Healthcare's board of directors increases from nine to ten members. Mr. Chidsey will serve as a member of HCA Healthcare's audit and compliance committee, compensation committee and patient safety and quality of care committee. Mr. Chidsey most recently served as the global chief executive officer of Subway. He previously served as chief executive officer of Burger King Holdings, Inc. and held significant leadership roles at Cendant Corporation. Earlier
HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that the HCA Healthcare Foundation has helped Girl Scouts of the USA (GSUSA) launch a new series of Mental Wellness Patch Programs to address mental wellness among girls in 4th through 12th grade. This is a result of the HCA Healthcare Foundation's $1.38 million grant to GSUSA, through its Healthier Tomorrow Fund, which was announced last year. "The HCA Healthcare Foundation has a long history of partnering with Girl Scouts nationally and locally. We are proud to deepen our partnership with Girl Scouts on this research-based mental wellness program," said Joanne Pulles, vice president of com
SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)
SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)
SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)